NCT07406971RecruitingPhase 2
Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke
Safety of Transmucosal Capsaicin for Chemical Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke Within 24 Hours of Symptom Onset: A Randomized Double-Blind Placebo-Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This study will evaluate the safety and tolerability of a dissolvable oral film containing a very small dose of capsaicin (the compound that produces the "hot" sensation in chili peppers) in adults with acute ischemic stroke. The film is designed to stimulate nerves in the mouth that may activate the sphenopalatine ganglion, a structure involved in regulating blood flow to the brain. The main purpose of this study is to determine whether the capsaicin film can be given safely to patients with acute ischemic stroke when started within 24 hours of symptom onset. Participants will be randomly assigned (like flipping a coin) to receive either the capsaicin oral film or a placebo film that looks and tastes similar but contains no capsaicin. Neither the participants nor the clinical team will know which film is given (double-blind). All participants will continue to receive standard medical care for acute ischemic stroke. After administration of the study film, participants will be closely monitored for side effects and changes in vital signs (blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation) at prespecified time points up to 72 hours. The primary outcome is the frequency of adverse events related to the study product within 72 hours after treatment begins. Participants will also be followed clinically up to 3 months as part of usual stroke care. The results of this study will help determine whether this approach is safe and feasible, and whether further studies are warranted.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 6 Feb 2026
- Start date
- 1 Sept 2025
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Diseases
- Stroke
- NCT number
- NCT07406971
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 46
- From 1 Sept 2025 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Intracranial hemorrhage on neuroimaging.
- Severe impairment of consciousness judged by the investigator to preclude safe participation.
- Severe systemic disease that, in the investigator's judgment, may interfere with study participation or safety.
Other
- Persistent blood pressure \>220/120 mmHg after initial medical management.
Who the study is looking for
- Age between 18 and 80 years.
- National Institutes of Health Stroke Scale (NIHSS) score between 6 and 20 at screening.
- Symptom onset within 24 hours prior to study intervention.
- Pre-stroke modified Rankin Scale (mRS) score ≤1.
- Provision of written informed consent by the participant or legally authorized representative.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centenario Hospital Miguel Hidalgo Coordinator of this site? Confirm its status | Aguascalientes | Mexico | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.